Clinical trial
A Randomized, Double-blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Escalating Doses of SAN-300 in Patients With Active Rheumatoid Arthritis With Inadequate Response to Disease-Modifying Anti-rheumatic Drug(s).
NCT02047604 is registered in ClinicalTrials.gov with Bausch Health Americas, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Escalating Doses of SAN-300 in Patients With Active Rheumatoid Arthritis With Inadequate Response to Disease-Modifying Anti-rheumatic Drug(s).
- Lead sponsor
- Bausch Health Americas, Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- December 31, 2013
- Completion date
- March 23, 2017
- Enrollment
- 41 (actual)
- Sites
- 12
Conditions
As the registry lists them; a condition with its own page is linked.
rheumatoid arthritis